Recombinant Somatropin
PreclinicalSmall molecule
Merck & Co.Recombinant Somatropin is one of 42 small molecule programs targeting Small for gestational age. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1Lovenox
SanofiPreclinical
Aricept
EisaiPreclinical
Zolymbus
AbbViePreclinical
Zyloprim
Alnylam PharmaceuticalsPreclinical
Somavaratan
Novo NordiskPreclinical
Glucophage
EMD SeronoPreclinical
Accutane
CConrado Roberto Hoffmann Filho
Preclinical
Glucagon
XXeris Pharmaceuticals
Preclinical
Prilosec
DDexcel Pharma Technologies Ltd.
Preclinical
Trental
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Recombinant Somatropin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company